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Clinical PerspectiveWhat Is New?In this study we describe how mutations in the *POT1* gene, which explain long telomeres, correlate with cell cycle arrest increase in angiosarcoma patients.The same increase was observed in other cardiac angiosarcoma patients even without mutations in the *POT1* gene but in the damage response signaling.This malfunction would bypass the apoptosis mechanism and would trigger the acquisition of somatic activating mutations in the angiogenesis pathway.What Are the Clinical Implications?Our results suggest that the use of angiogenesis inhibitors might regulate the tumor progression; however, targeting ATM/ATR (ataxia telangiectasia mutated/RAD3‐related) activity would rescue the cell cycle control and would prevent the acquisition of somatic driver mutations in patients affected with angiosarcoma tumors and asymptomatic patients carrying *POT1* mutations.

Introduction {#jah34407-sec-0008}
============

The Li‐Fraumeni syndrome is an autosomal dominant syndrome representing a genetic predisposition to a wide spectrum of tumors and is typically linked to mutations of the *TP53* tumor suppressor gene.[1](#jah34407-bib-0001){ref-type="ref"} Li‐Fraumeni‐like families have a similar clinical presentation, but Li‐Fraumeni‐like syndrome is less frequently associated with mutations in the *TP53* gene. Recently, we studied different Li‐Fraumeni‐like families with multiple tumors including various cases of cardiac angiosarcoma (CAS), which is the most common and most aggressive type of primary malignant neoplasm of the heart in adults.[2](#jah34407-bib-0002){ref-type="ref"} Patients affected with CAS are generally diagnosed at advanced stages with very poor prognosis and short survival rates (5‐year survival rate of 14%).[3](#jah34407-bib-0003){ref-type="ref"} The genetic landscape that determines the tumorigenic process of angiosarcomas (AS) is poorly understood and not well established.[4](#jah34407-bib-0004){ref-type="ref"}, [5](#jah34407-bib-0005){ref-type="ref"} Previous studies by our group uncovered a deleterious missense mutation in the *POT1* gene (c.349C\>T \[p.Arg117Cys\], pathogenic, Li‐Fraumeni‐like syndrome/CAS, autosomal dominant)[6](#jah34407-bib-0006){ref-type="ref"} causing AS in 4 families (3 in cardiac tissue and 1 in breast).[6](#jah34407-bib-0006){ref-type="ref"} Germline mutations in the *POT1* gene have also been related with the development of other familial cancer types.[7](#jah34407-bib-0007){ref-type="ref"}, [8](#jah34407-bib-0008){ref-type="ref"}, [9](#jah34407-bib-0009){ref-type="ref"}, [10](#jah34407-bib-0010){ref-type="ref"}, [11](#jah34407-bib-0011){ref-type="ref"}, [12](#jah34407-bib-0012){ref-type="ref"} POT1 is a component of the so‐called shelterin complex, which is involved in telomere elongation in germline and stem cells (Figure [1](#jah34407-fig-0001){ref-type="fig"}A).[13](#jah34407-bib-0013){ref-type="ref"} In normal conditions the shelterin complex protects telomere cap ends in somatic cells by preventing access of the telomerase to chromosome ends.[14](#jah34407-bib-0014){ref-type="ref"} The shelterin complex also masks single‐stranded telomeres from the DNA damage response, thereby preventing the activation of ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia RAD3‐related) to avoid cell cycle arrest through POT1 and TPP1 (Figure [1](#jah34407-fig-0001){ref-type="fig"}B).[15](#jah34407-bib-0015){ref-type="ref"} *TPP1* (which is also called *ACD* gene) anchors the telomere by POT1 and TRF1 (telomeric repeat binding factor 1) proteins. When telomeres are critically short, the shelterin complex does not prevent activation of the ATM and ATR response, which can drive the cell to senescence and apoptosis (Figure [1](#jah34407-fig-0001){ref-type="fig"}C).

![Telomere biology and damage signaling. **A**, Elongation in germline/stem cells. The shelterin complex mediates telomere elongation by recruiting telomerase. Shelterin also represses the DNA damage response by preventing the activation of ATM and ATR through TPP1 and POT1 proteins, respectively. TPP1 is anchored to the chromosome by POT1 and TRF (telomeric repeat binding factor 1), which is another component of the shelterin complex. **B**, Telomere shortening in somatic cells. Somatic divisions entail telomere shortening due to the inhibition of telomerase recruitment mediated by the POT1 protein. **C**, Extremely short telomere. The shelterin complex cannot bind critically short telomeres. DNA damage response ATM/ATR activates the TP53/p21 cascade to inhibit CDK1/2. DNA damage markers such as γH2AX and TP53BP1 bind the short telomeres. DNA damage signaling mediates senescence, cell cycle arrest, and apoptosis. **D**,*POT1* p.Arg117Cys (p.R117C) mutation carriers. The *POT1* p.R117C mutation prevents POT1 from binding to TPP1 and from forming the OB‐fold to bind single‐strand DNA, which prevents POT1 from repressing ATR signaling. Telomere damage response is activated in *POT1* p.R117C mutation carriers.](JAH3-8-e012875-g001){#jah34407-fig-0001}

Our previous studies demonstrated that cardiac angiosarcoma patients carrying the *POT1* p.Arg117Cys mutation showed abnormally long telomeres due to the lack of repression of telomerase, which led to increased fragility and damage.[6](#jah34407-bib-0006){ref-type="ref"} Other described *POT1* mutations associated with risk of developing familial glioma and familial melanoma tumors also led to abnormally long and fragile telomeres.[7](#jah34407-bib-0007){ref-type="ref"} However, the link between telomere instability and tumorigenesis is not well understood. In addition, studies of the biological pathways involved in the progression of angiosarcomas are very scarce. Recently, next‐generation sequencing studies uncovered somatic alterations in the VEGF/PLCG1 pathway in cardiac angiosarcoma[16](#jah34407-bib-0016){ref-type="ref"}, [17](#jah34407-bib-0017){ref-type="ref"} and driver mutations in the PI3K/AKT/mTOR and MEK pathways in angiosarcomas other than cardiac,[18](#jah34407-bib-0018){ref-type="ref"}, [19](#jah34407-bib-0019){ref-type="ref"}, [20](#jah34407-bib-0020){ref-type="ref"}, [21](#jah34407-bib-0021){ref-type="ref"} but these studies did not distinguish between constitutive and somatic mutations and did not clarify the genetics and underlying mechanisms.

In order to understand how telomere instability links the angiosarcoma process, in the present work we studied somatic events in different angiosarcoma patients carrying the *POT1* p.Arg117Cys mutation described in Calvete et al[6](#jah34407-bib-0006){ref-type="ref"}: 2 patients (F1 and F3) affected with CAS and 1 patient (F2) with 2 tumors, a breast AS and a papillary thyroid tumor. In addition, we studied the genetic and molecular somatic landscape that drives tumor progression in 7 patients with sporadic CAS tumors (NT1‐NT3 and T1 to T4) who did not carry mutations in the *POT1* gene.

Methods {#jah34407-sec-0009}
=======

The data, methods used in the analysis, and materials used to conduct the research are available to any researcher for purposes of reproducing the results or replicating the procedure.

Ethics Statement {#jah34407-sec-0010}
----------------

Institutional Review Board approval was obtained; the ethics committee of the CNIO, the Institute of Health Carlos III, and SaludMadrid (Autonomous Community of Madrid) approved this study (CS9679). Informed consent was received from participants before inclusion in the study.

Patients {#jah34407-sec-0011}
--------

Formalin‐fixed paraffin‐embedded (FFPE) tissue samples from 10 patients were selected. The 3 familial angiosarcoma individuals carrying the *POT1* p.Arg117Cys mutation were selected from Calvete et al.[6](#jah34407-bib-0006){ref-type="ref"} Seven FFPE tissue samples from individuals affected with sporadic CAS not carrying mutations in the *POT1* gene were also selected: 3 FFPE tissue sections contained normal (N) and tumor (T) tissue (NT1, NT2 and NT3), and the other 4 FFPE sections contained only tumor tissue (T1 to T4).

Samples {#jah34407-sec-0012}
-------

Genomic DNA was extracted from FFPE tissue samples and from fixed tissue slides (microdissection) using the DNeasy Blood & Tissue Kit (Cat No. 69504, Qiagen, Hilden, Germany) following the manufacturer\'s instructions. Histology of hematoxylin and eosin--stained sections of the tissues was assessed by a pathologist (M.M.).

Immunohistochemistry {#jah34407-sec-0013}
--------------------

FFPE blocks were cut into 5‐μm‐thick sections for immunohistochemistry (IHC) studies. The cell cycle in normal tissue was tested with anti‐p21 (WAF1) from Merck (Darmstadt, Germany; Ref MABE325), anti‐p27 (57/Kip1) from BD Biosciences (Franklin Lakes, NJ; Ref 610242), and anti--phosphohistone γH2AX (Ser139) from Millipore (Burlington, MA; Ref 05‐636) antibodies. Activation of the VEGF‐angiogenesis pathway was assessed with 2 different antibodies against phosphorylated (activated) proteins: anti--phospho‐p44/42‐MAPK (ERK1/2) and anti--phospho‐S6 ribosomal protein (Ser235/236) from Cell Signaling Technology (Danvers, MA; Refs 9101 and 2211, respectively). Both the absence of staining and excess nonspecific staining were considered as negative staining. Staining was considered separately in normal (N) and tumor (T) tissues. IHC controls were performed by using normal tissue from biopsies of healthy individuals.

Whole Exome Sequencing and Bioinformatics Pipelines {#jah34407-sec-0014}
---------------------------------------------------

Exomes from selected tissues were captured and enriched using the SureSelect Human All Exon Kit (78 Mb) (Agilent Technologies, Santa Clara, CA). Enriched samples were paired‐end sequenced on an Illumina Genome Analyzer II sequencing platform using 2 lanes per sample and generating 101 base‐pair long reads. FASTQ files of short reads were aligned using the BWA algorithm to the GRCh37/hg19 reference genome[22](#jah34407-bib-0022){ref-type="ref"}; 96.11% (ranging from 93.34% to 98.74%) of the reads aligned in the reference genomes (effectiveness). GATK‐based variant calling was performed for aligned reads considering DP (Read Depth) values of \>30 and Quality‐by‐Depth scores for a variant confidence of \>1.00. A total of 92.28% (ranging from 91.70% to 92.16%) of the variants that were well aligned and annotated passed the quality and coverage filters. Strict filtering for only well‐defined variants by quality controls, and those not included in repeat regions were included to prevent false positives. Tumor variants (\<10% alternative variant allele frequency) and those with low coverage (\<6×) were discarded.

Only quality‐filtered variants affecting coding sequences of canonical transcripts (nonsynonymous, essential splice site, frame shift or gain/loss of stops) were taken into account. Variant type annotation, population statistics, disease‐specific sequence databases, and in silico predictive algorithms were according to AMCG standards and guidelines.[23](#jah34407-bib-0023){ref-type="ref"} Variants with a minor allele frequency of \<0.01 and \<0.05 (dbSNP130, HapMap, or 1000 Genomes) were considered for stringent and relaxed filtering, respectively. Their potential damaging effect was assessed using the VEP[24](#jah34407-bib-0024){ref-type="ref"} script software package (including Sift, Polyphen and Condel damage predictors). Stringent filtering only considered the variants annotated as pathogenic by all damage predictors. Whole‐exome sequencing data have been deposited in the ArrayExpress public database under accession number E‐MTAB‐7999 (available at <https://www.ebi.ac.uk/fg/annotare/>).

Variants found in DNA blood samples and variants found in common between paired normal/tumor tissues were considered as constitutional. Variants found only in tumor tissue were considered somatic variants. Constitutional variants were validated in DNA from blood and normal tissue samples, and somatic variants were validated in DNA from tissue samples (tumor) by Sanger sequencing.

Pathway Enrichment Analyses {#jah34407-sec-0015}
---------------------------

Two different software packages were used for independent assessments of the gene set analyses. Data were analyzed with Qiagen\'s Ingenuity Pathway Analysis (IPA, Qiagen, Redwood City, CA [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)) and ConsensusPathDB (available at <http://cpdb.molgen.mpg.de/>).[25](#jah34407-bib-0025){ref-type="ref"} Overrepresentation analysis of the gene set list was performed with a minimum overlap of 4 genes with the pathway database set size and a *P*‐value cutoff of 0.001. Induced network module analysis without intermediate nodes and considering high‐confidence binary protein and genetic/gene regulatory interactions were also evaluated.

Trusight Tumor 170 Panel and IBM Watson Study {#jah34407-sec-0016}
---------------------------------------------

Resequencing of tumor DNA from FFPE tissue samples was performed with TruSight Tumor 170 from Illumina (San Diego, CA), a novel sequencing platform that predicts the most probable variant causing the pathology and provides suggestions for translating the data to the clinic. The sequencing of the hybrid capture was run on the HiSeq 2500 System. The captured gene content in the TruSight Tumor 170 Assay, data sheet, and specifications are available at <https://www.illumina.com>. Low variant quality of \<20 and low depth (\<100 for variant calls and \<250 for reference call filters) were considered. Variants were supported with \>7 reads and filtered by frequency (minor allele frequency \<0.05). The copy number variation call was calculated for the fold‐change results for each gene. Variants were classified and analyzed later by the IBM Watson for Genomics platform, which searches electronic medical databases to find information that may be relevant to a particular genomic sequence (available at <https://www.ibm.com/watson/>).

Results {#jah34407-sec-0017}
=======

Angiosarcoma Patients Carrying the *POT1* p.Arg117Cys Mutation {#jah34407-sec-0018}
--------------------------------------------------------------

### Constitutional Effect in Normal Tissue of *POT1* p.Arg117Cys Mutation Carriers {#jah34407-sec-0019}

In normal conditions the POT1 protein represses downstream activation of the DNA damage response at telomeres in somatic cells (Figure [1](#jah34407-fig-0001){ref-type="fig"}B).[15](#jah34407-bib-0015){ref-type="ref"} The POT1 p.Arg117Cys protein shows a reduced capacity to bind telomeres and TPP1[6](#jah34407-bib-0006){ref-type="ref"} and may affect the regulation of the damage response. Damage response activation leads to cell cycle arrest, replicative senescence, and apoptosis (Figure [1](#jah34407-fig-0001){ref-type="fig"}C). In order to decipher the putative effect of POT1 malfunction, patient tissues were stained with anti‐P‐γH2AX (DNA damage marker) and anti‐p21 and anti‐p27 antibodies (inhibitors of CDK1/2 to arrest the cell cycle). IHC studies were carried out in normal (N) tissues of patients from the families carrying the constitutional *POT1* p.Arg117Cys mutation studied in Calvete et al[6](#jah34407-bib-0006){ref-type="ref"}: 2 patients (F1 and F3) affected with CAS and 1 patient (F2) with 1 breast AS and 1 papillary thyroid tumor.

Increased IHC staining with anti‐p21, ‐p27, and ‐P‐γH2AX antibodies was observed in N tissues of all studied patients in comparison with the corresponding N tissues from healthy non--mutation carriers (Table [1](#jah34407-tbl-0001){ref-type="table"} and Figure [2](#jah34407-fig-0002){ref-type="fig"}A). Therefore, the reduced binding to telomeres and to TPP1 by the POT1 p.Arg117Cys protein correlates with activation of damage response signaling mediated by p21 and p27 (Figure [1](#jah34407-fig-0001){ref-type="fig"}D).

###### 

Total Cases and Number of Variants Found in the Whole Exome Sequencing

                                         Individual          Pathology      Tissue    Variant Calling   Filtered Variants   Somatic Variants[a](#jah34407-note-0003){ref-type="fn"}   Constitutional Variants[b](#jah34407-note-0004){ref-type="fn"}
  -------------------------------------- ------------------- -------------- --------- ----------------- ------------------- --------------------------------------------------------- ----------------------------------------------------------------
  *POT1* p.Arg117Cys carriers            F1                  CAS            T                           1095                46                                                        NA^+^
                                                             N                                                                                                                        
  F2                                     Papillary thyroid   T              100 506   1294              5                   NA^+^                                                     
                                                             N              100 371   1281                                                                                            
                                         Breast AS           T              93 496    1276              13                  NA^+^                                                     
  Without mutations in the *POT1* gene   NT1                 Sporadic CAS   T         102 560           1266                62                                                        1032
                                                             N              111 686   1333                                                                                            
  NT2                                    Sporadic CAS        T              100 120   1231              36                  1101                                                      
                                                             N              141 248   1239                                                                                            
  NT3                                    Sporadic CAS        T              97 233    704               37                  1180                                                      
                                                             N              113 358   762                                                                                             

                                                                   Individual     Pathology      Tissue    Variant Calling   Filtered Variants   Stringent Filtering
  ---------------------------------------------------------------- -------------- -------------- --------- ----------------- ------------------- ---------------------
  Only T tissue available[c](#jah34407-note-0005){ref-type="fn"}   T1             Sporadic CAS   T         93 374            1181                315
  T2                                                               Sporadic CAS   T              95 492    1274              403                 
  T3                                                               Sporadic CAS   T              104 545   1328              443                 
  T4                                                               Sporadic CAS   T              93 859    1233              361                 

CAS indicates cardiac angiosarcoma; N, normal tissue; NA^+^, not applicable (*POT1* p.Arg117Cys carriers from Calvete et al \[2015\]); T, tumor tissue.

Variants found in tumor tissue that were not found in normal tissue.

Variants found in normal tissue that were not found in tumor tissue.

Individuals with only T tissue sequenced.

![Immunohistochemical staining. **A**, Tissue stress was tested in normal tissue of carriers of the *POT1* p.Arg117Cys (p.R117C) mutation and carriers of mutations in the damage response‐signaling pathway (sporadic CAS) in comparison with the corresponding normal tissue without mutations (wild type). Above: Wild‐type cardiac and thyroid tissues from healthy controls without mutations. Below: normal tissue of individual NT2 (sporadic CAS individual with constitutional mutations in the *ATR*,*ATM* and *TP53BP* genes) and normal tissue of individual F2 (papillary thyroid tumor with *POT1* p.R117C mutation) as representative examples (see Table [2](#jah34407-tbl-0002){ref-type="table"} for all studied individuals). Increased cell cycle arrest was observed in the normal tissue of both patients. Black arrowheads show some of the stained nuclei. Detailed fields (10×) are also shown. Scale bar (in black): 100 μm. **B**,IHC staining with anti--P‐ERK and anti--P‐S6 antibodies in tumor tissues. Tumor tissues from carriers (F1 and F2) and noncarriers (T1 and NT2) of the *POT1* p.R117C mutation compared with a normal tissue section (negative staining) are shown as examples (see Table [2](#jah34407-tbl-0002){ref-type="table"} for all studied individuals). Three tumors from the 2 patients (F1 and F2) carrying the *POT1* p.R117C mutation are shown: both angiosarcomas (CAS tumor tissue from F1 and breast AS from patient F2) only showed immunoreactivity with anti--P‐S6 antibody, while the papillary thyroid tumor (patient F2) also showed immunoreactivity with anti--P‐ERK antibody. Two staining patterns were observed in sporadic CAS patients without mutations in the *POT1* gene: tissue from patient T1 only showed immunoreactivity with anti--P‐S6, whereas tissue from patient NT2 (sporadic CAS) was stained with both anti--P‐S6 and anti--P‐ERK antibodies. Scale bar (in black): 100 μm. AS indicates angiosarcoma; CAS, cardiac angiosarcoma; N, normal tissue; T, tumor tissue.](JAH3-8-e012875-g002){#jah34407-fig-0002}

### Somatic Events in *POT1* p.Arg117Cys Mutation Carriers {#jah34407-sec-0020}

To evaluate possible somatic events in affected individuals carrying the *POT1* p.Arg117Cys mutation that might lead to the formation of AS, the exomes of normal (N) and tumor (T) tissues of the F1 and F2 individuals were sequenced. Variants found in T tissue but not in N tissue were considered to be somatic ([Table S1](#jah34407-sup-0001){ref-type="supplementary-material"}). In patient F1 (CAS), 46 filtered somatic variants were found in T but not in N cardiac tissue (Table [2](#jah34407-tbl-0002){ref-type="table"}) including an in‐frame deletion in the *KDR* gene (p.Asn704del), which encodes VEGF receptor 2 (VEGFR2), which belongs to the VEGF‐angiogenesis signaling pathway (Figure [3](#jah34407-fig-0003){ref-type="fig"}A and [3](#jah34407-fig-0003){ref-type="fig"}B).

###### 

Immunohistochemistry Staining Results for the Studied Cases

  Mutation      Sample   Pathology   Tissue           N Tissue   Mutations in VEGF‐Angiogenesis Pathway   T Tissue                             
  ------------- -------- ----------- ---------------- ---------- ---------------------------------------- ---------- ------------------- ----- ----
  *POT1*        F1       CAS         Cardiac (N+T)    \+         \+                                       \+         *KDR*               *−*   \+
  p.Arg117Cys   F2       Breast AS   Breast T         NA         NA                                       NA         *PI3K*              *−*   \+
                                     Thyroid (N +T)   \+         \+                                       \+         *BRAF*              \+    \+
  DR genes      NT2      CAS         Cardiac (N+T)    \+         \+                                       \+         VEGF2/RAS‐MAPK      \+    \+
                T1       CAS         Cardiac (T)      NA         NA                                       NA         Akt‐PI3K            *−*   \+
                T3       CAS         Cardiac (T)      NA         NA                                       NA         RAS‐MAPK/Akt‐PI3K   \+    \+
                T4       CAS         Cardiac (T)      NA         NA                                       NA         VEGFA/Akt‐PI3K      \+    \+

\+ indicates overexpression; *−*, no expression; CAS, cardiac angiosarcoma; DR, damage response; N, normal; NA, tissue not available; T, tumor.

Positive staining in lining epithelium and tissue.

![VEGF (vascular endothelial growth factor)‐angiogenesis signaling and cell cycle regulation pathways. VEGF signaling is a growth factor pathway to stimulate vasculogenesis and angiogenesis. **A**,MAPK/ERK signaling regulates cell proliferation. **B**,AKT/PI3K signaling is related to protein synthesis and cell cycle signaling. Locations of anti--P‐ERK and anti--P‐S6 used in IHC studies are also shown in the pathway (white arrows). **C**, Damage‐signaling pathway. AKT/PI3K signaling inhibits apoptosis, senescence, and cell cycle arrest through inhibition of FOXO, which in turn positively regulates p21 and p27 activity.](JAH3-8-e012875-g003){#jah34407-fig-0003}

Regarding the F2 individual, only 13 filtered somatic variants were found in the T tissue of the breast AS ([Table S1](#jah34407-sup-0001){ref-type="supplementary-material"}). Two of them were variants annotated in the genes *PLCG1* (p.Leu752Val) and *PIK3CA* (p.Arg88Gln) belonging to the VEGF‐angiogenesis pathway and previously described to be involved in different angiosarcomas and primary breast cancer.[26](#jah34407-bib-0026){ref-type="ref"} Another 5 somatic variants were found in the papillary thyroid T tissue from the same individual ([Table S1](#jah34407-sup-0001){ref-type="supplementary-material"}). Three of these belonged to the VEGF‐angiogenesis pathway (*PIK3R6* \[p.Arg59Lys\], *RASSF1* \[p.Arg227His\], and *BRAF* \[p.Val600Glu\]). Overall, 32/52 (62%) of the somatic missenses were C:G\>T:A changes ([Table S1](#jah34407-sup-0001){ref-type="supplementary-material"}). Genes with mutations are shown in the angiogenesis pathway depicted in Figure [3](#jah34407-fig-0003){ref-type="fig"}.

Finally, only cardiac tumor tissue from patient F3 (CAS) was sequenced (Table [2](#jah34407-tbl-0002){ref-type="table"}). A total of 297 filtered variants were found in the tumor tissue of this patient ([Table S2](#jah34407-sup-0001){ref-type="supplementary-material"}), including another mutation in the *KDR* gene (p.Thr771Arg). Overall, 60% of the somatic variants found in patient F3 were annotated as C:G\>T:A changes ([Table S2](#jah34407-sup-0001){ref-type="supplementary-material"}).

Thus, somatic mutations in the VEGF signaling pathway were found in the tumor tissues of all affected individuals carrying the *POT1* p.Arg117Cys germline mutation. Interestingly, both studied CAS patients had mutations in *KDR*, which activates VEGF signaling to regulate angiogenesis by the MAPK/ERK and AKT/PI3K pathways (Figure [3](#jah34407-fig-0003){ref-type="fig"}A and [3](#jah34407-fig-0003){ref-type="fig"}B). MAPK/ERK regulates proliferation activity, while AKT/PI3K promotes protein synthesis. Interestingly, both molecular activities regulate the cell cycle by inhibiting senescence promotion (Figure [3](#jah34407-fig-0003){ref-type="fig"}C). In order to test the putative effects of the mutations found in the VEGF angiogenesis pathway, we studied the MAPK/ERK and AKT/PI3K molecular pathways by IHC with antibodies against the activated (phosphorylated) forms of ERK and S6, respectively (Figure [3](#jah34407-fig-0003){ref-type="fig"}A and [3](#jah34407-fig-0003){ref-type="fig"}B). All angiosarcomas (CAS and the breast AS tumors) did not stain with anti--P‐ERK but were positively stained (\>70%) with the anti--P‐S6 antibody. However, papillary thyroid tumor tissue stained with both antibodies (Table [1](#jah34407-tbl-0001){ref-type="table"} and Figure [2](#jah34407-fig-0002){ref-type="fig"}B).

In summary, somatic activating mutations of the VEGF‐angiogenesis pathway were found in all studied tumor tissues of *POT1*‐mutated patients independently of the tumor type (cardiac, breast, and thyroid). Somatic mutations in the *KDR* gene were found in both CAS patients (F1 and F3). In addition, positive P‐S6 staining was observed in all angiosarcomas with somatic mutations in the *KDR* (CAS) and *PI3K* (breast AS) genes (AKT/PI3K pathway). The papillary tumor (F2), which had a mutation in the MAPK/ERK signaling pathway (*BRAF* gene), was stained with both anti--P‐ERK and anti‐PS6 antibodies (Figures [2](#jah34407-fig-0002){ref-type="fig"}B and [3](#jah34407-fig-0003){ref-type="fig"}).

Sporadic Cardiac Angiosarcoma Patients Without Mutations in the *POT1* Gene {#jah34407-sec-0021}
---------------------------------------------------------------------------

To assess the whole genetic landscape of CAS tumors, another 7 patients with sporadic CAS tumors who were not carrying mutations in the *POT1* gene were studied. Normal (N) and tumor (T) cardiac tissues were available from 3 sporadic CAS individuals (NT1, NT2, and NT3), whereas only tumor tissue was available from the other 4 CAS individuals (T1 to T4). We found 1032, 1101, and 1180 constitutional variants in cardiac tissue for the NT1, NT2, and NT3 CAS individuals, respectively; 62, 36, and 37 somatic variants were found for individuals NT1, NT2, and NT3, respectively (Table [2](#jah34407-tbl-0002){ref-type="table"}).

Regarding the 4 tumor samples of which only T tissue was available, no distinction could be made between constitutional and somatic variants. We found 1181, 1274, 1328, and 1233 variants in the T tissue of patients T1, T2, T3, and T4, respectively (Table [2](#jah34407-tbl-0002){ref-type="table"}).

To further delineate the genetic landscape of sporadic CAS tumors, the genes encompassing filtered variants were grouped into 2 different pathway enrichment analyses. The first set included genes with constitutional (found in both N and T tissues from cases NT1, NT2, and NT3) and all genes with variants from the other 4 CAS individuals with only the tumor tissue sequenced (constitutional or somatic) (2501 unique genes in total); the second set included the genes with somatic variants (only present in T tissue) from cases with N and T tissue (NT1, NT2, and NT3) and again all genes with variants from the other 4 CAS individuals with only the sequenced T tissue cases (T1 to T4) (1522 unique genes in total).

### Constitutional Events in Normal Tissue in Sporadic CAS {#jah34407-sec-0022}

This study revealed that the most represented pathway and the pathway with the major number of genes were the "Sustainability of p53 pathway" (genes *ATM*,*TP53,* and *RFWD2*) (*P* value 0.003) and the "Repair modulation pathway" (genes *ATR, ATM, TP53, RFWD2, SIRT7, BRCA2, CDK8, UBE2D1, WRN, PMS2, BRIP1, TP53BP2,* and *APC2*) (*P* value 0.0022), respectively ([Table S3](#jah34407-sup-0001){ref-type="supplementary-material"}). Mutations in genes from these pathways were found in all 7 sporadic CAS individuals (Figure [4](#jah34407-fig-0004){ref-type="fig"}). These genes belong to the damage response signaling pathway and may deregulate the cell cycle in the same manner as previously observed for the *POT1* mutation carriers. Thus, N cardiac tissue from the sporadic CAS individuals (NT series) was also stained with anti--P‐γH2AX, anti‐p21, and anti‐p27 antibodies. Positive staining was also observed in N tissue of sporadic CAS individuals (Table [1](#jah34407-tbl-0001){ref-type="table"}), which correlated with cell cycle deregulation as observed in familial angiosarcomas (*POT1* p.Arg117Cys mutation carriers). Therefore, the familial angiosarcomas (*POT1* p.Arg117Cys carriers) and sporadic CAS patients behaved in a similar way regarding cell cycle arrest regulation.

![Genes with mutations in the studied CAS individuals. Genes are distributed considering the gene ontology among telomere instability and damage response or VEGF (vascular endothelial growth factor)‐angiogenesis signaling pathways. Exomes from normal/tumor tissues of 3 patients (F1, F2, and F3) carrying the constitutional *POT1* p.Arg117Cys mutation (orange) and 3 sporadic CAS individuals not carrying mutations in the *POT1* gene (NT1, NT2, and NT3) were sequenced. Constitutional mutations refer to variants found in blood samples and found in common in both N and T tissues (red). Mutations found only in tumor tissue were considered somatic (purple). Only tumor tissue from another 4 sporadic CAS individuals (T1 to T4) was also sequenced. A distinction between first event and somatic variants could not be made for the mutations found in these individuals (blue). Less stringent frequency filtering corresponds to a minor allele frequency \<0.05 (light purple) instead of \<0.01 (light blue). AS indicates angiosarcoma; CAS, cardiac angiosarcoma; N, normal tissue; P. thyroid, papillary thyroid tumor; T, tumor tissue.](JAH3-8-e012875-g004){#jah34407-fig-0004}

### Somatic Events in Tumor Tissue in Sporadic CAS {#jah34407-sec-0023}

A second pathway enrichment analysis was performed with the gene set including the somatic variants found in T tissues of sporadic CAS individuals (see above). This enrichment analysis revealed that the most represented pathway was the "gf‐hypoxia and angiogenesis" pathway (Biocarta: 16.7%) (*P* value 0.00557). The pathway with the major number of affected genes was the "Signaling by VEGF" pathway (Reactome, 24 genes) (*P* value 0.00101) ([Table S3](#jah34407-sup-0001){ref-type="supplementary-material"}). Both enrichment analyses corresponded with the VEGF‐angiogenesis pathway. Genes with mutations are shown in the angiogenesis pathway of Figure [3](#jah34407-fig-0003){ref-type="fig"}. Mutations in genes from these pathways were found in all 7 sporadic CAS individuals (Figure [4](#jah34407-fig-0004){ref-type="fig"}). Activation of the MAPK/ERK and AKT‐PI3K pathways was studied by IHC with anti--P‐ERK and anti--P‐S6 antibodies, respectively.

Tumors of all studied sporadic CAS individuals (NT and T series) stained positive with anti‐PS6 antibodies, which demonstrates that somatic mutations were activating the VEGF‐angiogenesis pathway (Table [1](#jah34407-tbl-0001){ref-type="table"}). Especially intense staining was also observed in the endothelial lining of blood vessels. However, not all tissues from individuals affected with sporadic CAS stained with anti‐PERK antibody. Tissue of individual T1, who only had mutations in the AKT‐PI3K signaling pathway (Table [1](#jah34407-tbl-0001){ref-type="table"}), did not stain with anti--P‐ERK. The tumors with mutations in the 2 molecular signaling pathways (NT1, NT2, and T4) also stained positive with the 2 antibodies (anti--P‐ERK and anti--P‐S6) (Table [1](#jah34407-tbl-0001){ref-type="table"}). Interestingly, the individual with mutations only in the MAPK/ERK signaling pathway (T3) also stained positive with both antibodies (Table [1](#jah34407-tbl-0001){ref-type="table"}). Stained tissues from patients T1 and NT2 are shown in Figure [2](#jah34407-fig-0002){ref-type="fig"}B as representative examples.

In summary, all studied individuals with CAS (either familial or sporadic) had mutations (either constitutional or somatic) in normal tissue affecting damage response signaling (Figure [4](#jah34407-fig-0004){ref-type="fig"}). IHC with anti‐p21 and anti‐p27 antibodies confirmed cell cycle arrest deregulation in N tissue that leads to constitutional cell cycle arrest and cessation of cell division (Figure [2](#jah34407-fig-0002){ref-type="fig"}A and Table [1](#jah34407-tbl-0001){ref-type="table"}). In addition, somatic activating mutations in the VEGF‐angiogenesis pathway were found in tumor tissue of familial and sporadic angiosarcomas, independently of the presence of *POT1* mutations (Figures [2](#jah34407-fig-0002){ref-type="fig"}B and [4](#jah34407-fig-0004){ref-type="fig"}; Table [1](#jah34407-tbl-0001){ref-type="table"}).

Sequencing Replication With the Truseq170 Panel and IBM Watson for Genomics Platform {#jah34407-sec-0024}
------------------------------------------------------------------------------------

A sequencing replication was performed for 2 previously sequenced CAS patients without mutations in the *POT1* gene. The Truseq170 panel was run for tumor tissue of the T1 and T4 individuals and analyzed with the IBM Watson for Genomics platform (version 33.148), which is a novel sequencing platform that predicts the most probable variant causing the pathology and provides suggestions for translating the data to the clinic. The Watson for Genomics pipeline revealed 15 variants of unknown significance, 2 alterations without proposed therapies, and only 1 actionable alteration for patient T1 ([Table S4](#jah34407-sup-0001){ref-type="supplementary-material"}). Three variants of unknown significance, 3 alterations with no proposed therapies, and another 3 actionable alterations were described for patient T4 ([Table S5](#jah34407-sup-0001){ref-type="supplementary-material"}). Interestingly, a not previously detected copy number gain was found for the *KIT* gene in the tumor tissue of patient T1. The gained region is involved in tumor cell proliferation, angiogenesis, and metastatic disease. Only 1 actionable pathway was found in common for both CAS patients. The variants found in the *TP53* gene were highlighted as actionable alterations, as previously found in the WES study (*TP53* p.Arg175His and *TP53* p.Val143Met for patients T1 and T4, respectively). No Food and Drug Administration--approved therapies for angiosarcoma were recommended for these 2 patients, but 3 therapies with clinical trials were observed in common for both patients: AZD1775 (NCT numbers NCT02576444 and NCT018227384), Transferrin Receptor‐Targeted Liposomal p53 (NCT02354547), and Modified Vaccinia Virus Ankara Vaccine (NCT02432963). The 3 therapies for the alterations common to the 2 CAS patients target TP53 to restore cell cycle regulation.

Discussion {#jah34407-sec-0025}
==========

Telomere Instability in *POT1* Mutation Carriers Increases Cell Cycle Arrest in Constitutional Tissue and Increases Acquisition of Somatic Mutations in the Angiogenesis Pathway {#jah34407-sec-0026}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The single‐strand DNA response in telomeres is inactivated by the shelterin complex (Figure [1](#jah34407-fig-0001){ref-type="fig"}A and [1](#jah34407-fig-0001){ref-type="fig"}B).[15](#jah34407-bib-0015){ref-type="ref"} We previously observed that the *POT1* p.Arg117Cys mutation prevented the POT1 protein from binding to TPP1 and forming the OB‐fold to bind singles‐strand DNA, which led to abnormally long telomeres.[6](#jah34407-bib-0006){ref-type="ref"} Here, we observed that abnormal telomere length found in our patients correlates with a genomic instability scenario that, in consequence, activates DNA damage‐signaling (γH2AX‐positive staining). Individuals carrying the *POT1* p.Arg117Cys mutation overexpressed the p21 and p27 proteins in constitutional tissue (Table [1](#jah34407-tbl-0001){ref-type="table"}), which correlates with prevention of the repression of ATR signaling and leads to cell cycle arrest (Figure [1](#jah34407-fig-0001){ref-type="fig"}D). This increased senescence in nontumor tissue would result in reduced cell cycling and cessation of cell division. A similar mechanism was proposed to explain how short telomeres can lead to vascular senescence and diminished proliferative capacity that involved exhaustion of cell pools in mice.[27](#jah34407-bib-0027){ref-type="ref"}, [28](#jah34407-bib-0028){ref-type="ref"} In addition, tumor tissue of *POT1* p.Arg117Cys mutation carriers was studied in order to evaluate the involvement of constitutional cell cycle arrest in tumor progression. On average, 61% of the somatic variants found in these patients were C:G\>T:A changes ([Tables S1 and S2](#jah34407-sup-0001){ref-type="supplementary-material"}). At this time we cannot rule out a correlation between this observed bias and a specific mutation signature in these tumors. Megquier et al[29](#jah34407-bib-0029){ref-type="ref"} have established an association with somatic deamination of cytosine to thymine in a large series of angiosarcomas (different from cardiac), which is in agreement with our observation. Somatic mutations in the VEGF‐angiogenesis pathway were found in tumor tissue of all individuals (Figure [4](#jah34407-fig-0004){ref-type="fig"}). Interestingly, the F1 and F3 individuals (CAS) also had a somatic mutation in the *KDR* gene, which is involved in VEGF/PLCG1 activation and was described altered in 2 recently studied sporadic CAS cases.[16](#jah34407-bib-0016){ref-type="ref"}, [17](#jah34407-bib-0017){ref-type="ref"} In the F2 patient the recurrent somatic mutations *PIK3CA* p.Arg88Gln and *BRAF* p.Val600Glu were found in the breast AS and the papillary thyroid tumor, respectively. Twenty‐five percent of all breast cancers have somatic mutations in the *PIK3CA* gene. Specifically, the *PIK3CA* p.Arg88Gln mutation was described in a primary breast cancer.[26](#jah34407-bib-0026){ref-type="ref"} The somatic mutation *BRAF* p.Val600Glu is the most common genetic change in papillary thyroid cancers (35.8%).[30](#jah34407-bib-0030){ref-type="ref"} In addition, the *BRAF* p.Val600Glu and *PIK3CA* p.Arg88Gln mutations have been described as activators of the angiogenic response.[31](#jah34407-bib-0031){ref-type="ref"}, [32](#jah34407-bib-0032){ref-type="ref"} The somatic mutation *BRAF* p.Val600Glu has also been reported in gliomas[33](#jah34407-bib-0033){ref-type="ref"} and melanomas,[34](#jah34407-bib-0034){ref-type="ref"} where constitutional mutations in the *POT1* gene were also described.[10](#jah34407-bib-0010){ref-type="ref"}, [11](#jah34407-bib-0011){ref-type="ref"}, [12](#jah34407-bib-0012){ref-type="ref"} In summary, individuals with nonfunctional POT1 did not repress damage signaling (ATR) and showed a constitutive increase of p21 and p27 expression, which is in agreement with cell cycle arrest. In addition, somatic activating mutations in the angiogenesis pathway were acquired. Interestingly, activating somatic mutations in the *KDR* gene were found in both studied patients affected with CAS and carrying a *POT1* germline mutation (F1 and F3). This was also observed in other tissues and tumors different from cardiac angiosarcomas with mutations in the *POT1* gene (thyroid and breast from patient F2), demonstrating that not only in cardiac tissue is there a strong correlation between constitutional senescence mediated by POT1 malfunction and the acquisition of somatic mutations in the angiogenesis pathway.

Sporadic Cardiac Angiosarcomas Without *POT1* Mutations {#jah34407-sec-0027}
-------------------------------------------------------

Although in 4 of the 10 patients studied no discrimination between germline and somatic mutations could be made, mutations in the pathways that were affected by the mutation in the *POT1* gene at both the constitutional and the somatic level were also found in these patients.

Studied CAS individuals without constitutional mutations in the *POT1* gene presented mutations in genes that were involved in damage response signaling (ATM‐ATR‐TP53) (Figure [4](#jah34407-fig-0004){ref-type="fig"}). IHC studies with anti‐p21 and anti‐p27 antibodies confirmed the damage response activation in all sporadic CAS individuals (Table [1](#jah34407-tbl-0001){ref-type="table"} and Figure [2](#jah34407-fig-0002){ref-type="fig"}). Therefore, our results suggest a relation between telomere instability (familial CAS) and altered damage signaling (sporadic CAS) on 1 hand, and increased cell cycle arrest leading to the cessation of cell division on the other. Our observation is in agreement with previous studies in which overexpression of TP53 was detected by immunohistochemistry in 49% of angiosarcoma patients.[19](#jah34407-bib-0019){ref-type="ref"} Somatic activating mutations in the VEGF‐angiogenesis pathway were also found in tumor tissue of all sporadic CAS individuals (Figures [2](#jah34407-fig-0002){ref-type="fig"} and [4](#jah34407-fig-0004){ref-type="fig"}). Similar studies performed in angiosarcomas also uncovered somatic driver mutations in the VEGF/PLCG1 angiogenesis pathway.[18](#jah34407-bib-0018){ref-type="ref"}, [20](#jah34407-bib-0020){ref-type="ref"}, [21](#jah34407-bib-0021){ref-type="ref"}

Constitutional Cell Cycle Arrest May Fuel the Acquisition of Somatic Mutations in the Angiogenesis Pathway in Angiosarcomas {#jah34407-sec-0028}
---------------------------------------------------------------------------------------------------------------------------

Activation of damage signaling in both familial (*POT1* mutations carriers) and sporadic angiosarcomas (ATM‐ATR‐TP53 mutation carriers) induced constitutional senescence and reduced cell division (Figure [2](#jah34407-fig-0002){ref-type="fig"}). Our results strongly suggest a correlation between constitutional cell cycle arrest and the acquired somatic mutations in the VEGF‐angiogenesis pathway that drive angiosarcoma formation. Moreover, increased cell cycle arrest due to POT1 malfunction also uncovered somatic angiogenesis activation in tumors other than cardiac angiosarcomas. Damage response signaling and the VEGF‐signaling pathway are mutually regulated (Figure [3](#jah34407-fig-0003){ref-type="fig"}). Recently, telomere biology and the PI3K pathway (angiogenesis) were also shown to be functionally connected, and phosphorylation activity of the PI3K/AKT pathway was demonstrated to affect telomere stability in vitro.[35](#jah34407-bib-0035){ref-type="ref"} In vitro studies with stem cells from *Pot1a* knockout mice with increased telomere dysfunction also suggested a correlation with increased proliferation.[36](#jah34407-bib-0036){ref-type="ref"} Our results indicate that the observed cell cycle deregulation may interfere with apoptosis. This bypass of apoptosis would permit the acquisition of somatic mutations. In addition, cells carrying somatic mutations in genes involved in attenuating cell cycle arrest, which depletes progenitor stem cells in nontumor tissues, may undergo positive selection. A bypass of apoptosis was also suggested in studies in which POT1 was inactivated in vitro, and induced genomic instability enabled cancer cells to acquire additional mutations and conferred aggressive behavior. Attenuation of the damage response was suggested to allow tumor cells to bypass the proliferation defect imposed by POT1 inhibition.[36](#jah34407-bib-0036){ref-type="ref"} Therefore, under senescence conditions, activating somatic mutations in the angiogenesis pathway would acquire an important role to replenish the depleted tissue. However, the mutations found in the angiogenesis pathway would contribute to angiosarcoma formation and progression.

Clinical Significance of the Identified Mechanism {#jah34407-sec-0029}
-------------------------------------------------

Activation of the VEGF‐angiogenesis pathway was found in all studied individuals with AS (familial and sporadic). However, our IHC studies revealed 2 different staining patterns that correlated with the location of the somatic mutations (Figure [2](#jah34407-fig-0002){ref-type="fig"}). Tumors with mutations in the AKT‐PI3K signaling pathway (F1, F2, F3, and T1) were only positively stained with the anti‐P‐S6 antibody (Table [1](#jah34407-tbl-0001){ref-type="table"} and Figure [4](#jah34407-fig-0004){ref-type="fig"}). The individuals with mutations only in the MAPK/ERK signaling pathway (NT1, NT2 and the papillary thyroid tumor of F2) or in both molecular signaling pathways (T3 and T4) were positively stained with both antibodies (Table [1](#jah34407-tbl-0001){ref-type="table"}). Therefore, different somatic alterations regarding increased angiogenesis may occur in response to senescence. These results give important clues regarding the diagnosis and classification of angiosarcomas.

Our results also have an important clinical relevance regarding treatment and translational research. Inhibition of angiogenesis may be useful to stop tumor progression.[37](#jah34407-bib-0037){ref-type="ref"} However, angiogenesis inhibition would mitigate the effect of the driving somatic mutations but would not revert cell cycle arrest or the suggested bypass of apoptosis and would therefore not curtail the acquisition of new somatic mutations. Treatment with PI3K inhibitors of patient‐derived xenografts also showed increased telomeric DNA damage.[35](#jah34407-bib-0035){ref-type="ref"} Our results suggest that further studies regarding ATM/ATR, damage signaling and cell cycle inhibition activity might lead to recovering cell cycle control and preventing the acquisition of somatic mutations, including in asymptomatic patients carrying *POT1* mutations. Regarding this issue, the second sequencing experiment with the IBM Watson platform also pointed to the damage‐signaling pathway as a therapeutic target. Actionable variants in the *TP53* gene were highlighted in both studied CAS individuals (T1 and T4). Therefore, although somatic driver variants were found to occur in the angiogenesis pathway, only damage response signaling was found actionable for both studied angiosarcomas ([Tables S4 and S5](#jah34407-sup-0001){ref-type="supplementary-material"}).

In summary, our current results demonstrate that inhibition of *POT1* gene function and damage response malfunction both activate ATR‐dependent DNA damage signaling, which increases cell cycle arrest that would diminish cell proliferation in constitutional tissue, and that triggers somatic activating mutations in the angiogenesis pathway in angiosarcomas. Interestingly, our results and the 2 previously studied CAS patients[16](#jah34407-bib-0016){ref-type="ref"}, [17](#jah34407-bib-0017){ref-type="ref"} suggest a strong correlation between constitutional mutations in the *POT1* gene, somatic activating mutations in the *KDR* gene, and CAS development. Importantly, the same mechanism was observed in tumor types different from cardiac tumors for patients carrying *POT1* mutations and long telomeres (Figure [2](#jah34407-fig-0002){ref-type="fig"}). The significance of this mechanism needs to be further evaluated, and it is conceivable that *POT1* mutations lead to the same acquired somatic alterations in other tissues and tumor types such as glioma, melanoma, or colorectal cancer.[7](#jah34407-bib-0007){ref-type="ref"} Therefore, mutations found in the *POT1* gene and other genes involved in DNA damage‐response signaling (*ATR/ATM* and *TP53*) in the studied cardiac angiosarcomas correlate with constitutional cell cycle arrest, which would deplete the progenitor cells and trigger tissue stress. This tissue stress would give rise to a bypass of the apoptotic regulation, which permits the acquisition of multiple somatic events. In all studied CAS cases (patients with familial CAS carrying the *POT1* mutation and patients with sporadic CAS), somatic activating mutations were found in the angiogenesis pathway, which drives tumor formation. At a translational level, inhibition of angiogenesis might be useful to halt tumor progression. However, inhibition of angiogenesis would not reverse cell cycle arrest or the suggested bypass of apoptosis in constitutional asymptomatic tissue. Instead, the use of ATM/ATR activity inhibitors might restore cell cycle control and prevent the acquisition of somatic mutations.
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